DISEASE-ASSOCIATED SYSTEMIC COMPLICATIONS IN CHILDHOOD NEPHROTIC SYNDROME: A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.53555/ym3pbd77Keywords:
Nephrotic syndrome, Children, systemic complicationAbstract
Background: Nephrotic syndrome (NS) is characterized by massive proteinuria (more than 40 mg/m^2 per hour) which causes hypoalbuminemia (less than 30 g/L), hyperlipidemia, edema, and various other complications. This is caused by increased permeability due to damage to the basement membrane of the glomerulus of the kidney.
The aim: This study aims to show about Disease-Associated Systemic Complications in Childhood Nephrotic Syndrome.
Methods: By comparing itself to the standards set by the Preferred Reporting Items for Systematic Review and MetaAnalysis (PRISMA) 2020, this study was able to show that it met all of the requirements. So, the experts were able to make sure that the study was as up-to-date as it was possible to be. For this search approach, publications that came out between 2013 and 2023 were taken into account. Several different online reference sources, like Pubmed and SagePub, were used to do this. It was decided not to take into account review pieces, works that had already been published, or works that were only half done.
Result: In the PubMed database, the results of our search brought up 74 articles, whereas the results of our search on SagePub brought up 351 articles. The results of the search conducted for the last year of 2013 yielded a total 71 articles for PubMed and 202 articles for SagePub. The result from title screening, a total 22 articles for PubMed and 38 articles for SagePub. In the end, we compiled a total of 10 papers. We included five research that met the criteria.
Conclusion: Nephrotic syndrome is one of the most common kidney diseases in children. Patients with nephrotic syndrome experience protein loss that has a negative impact on various biological functions and can result in disease-related complications.
References
Saleem M, Bierzynska A. Recent advances in understanding and treating nephrotic syndrome. F1000Research. 2017;6:1–7.
Ticklay I, Muchemwa L. Burden of Paediatric Kidney Diseases in a Tertiary Care Hospital in Harare , Zimbabwe. 2023;
Bennett MR, Pleasant LT, Haffner C, Ma Q, Haffey WD, Ying J, et al. A novel biomarker panel to identify steroid resistance in childhood idiopathic nephrotic syndrome. Biomark Insights. 2017;12.
Liu Y, Yang R, Yang C, Dong S, Zhu Y, Zhao M, et al. Cyclophosphamide versus cyclosporine a therapy in steroidresistant nephrotic syndrome: A retrospective study with a mean 5-year follow-up. J Int Med Res. 2018;46(11):4506– 17.
Tamura H. Trends in pediatric nephrotic syndrome. World J Nephrol. 2021;10(5):88–100.
Iijima K, Sako M, Oba M, Tanaka S, Hamada R, Sakai T, et al. Mycophenolate Mofetil after Rituximab for Childhood-Onset Complicated Frequently-Relapsing or Steroid-Dependent Nephrotic Syndrome. J Am Soc Nephrol. 2022;33(2):401–19.
Ruggenenti P, Ruggiero B, Cravedi P, Vivarelli M, Massella L, Marasà M, et al. Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J Am Soc Nephrol. 2014;25(4):850–63.
Hilmanto D, Mawardi F, Lestari AS, Widiasta A. Disease-Associated Systemic Complications in Childhood Nephrotic Syndrome: A Systematic Review. Int J Nephrol Renovasc Dis. 2022;15(February):53–62.
Sinha A, Bagga A. Nephrotic syndrome. Indian J Pediatr. 2012;79(8):1045–55.
Basu B, Sander A, Roy B, Preussler S, Barua S, Mahapatra TKS, et al. Efficacy of rituximab vs tacrolimus in pediatric corticosteroid-dependent nephrotic syndrome a randomized clinical trial. JAMA Pediatr. 2018;172(8):757– 64.
Busuioc RM, Mircescu G. Nephrotic Syndrome Complications - New and Old. Part 1. Maedica (Buchar) [Internet]
;17(1):153–68. Available from: http://www.ncbi.nlm.nih.gov/pubmed/35733752%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=P MC9168581
Bennett MR, Pordal A, Haffner C, Pleasant L, Ma Q, Devarajan P. Urinary vitamin D-binding protein as a biomarker of steroid-resistant nephrotic syndrome. Biomark Insights. 2016;11:1–6.
Ali R, Baban R, Ali S. Evaluation of lipid metabolizing enzymes: Paraxonase1 (PON1) and lecithin cholesterol acyltransferase (LCAT) activities in children with nephrotic syndrome. Baghdad J Biochem Appl Biol Sci. 2021;2(01):48–59.
El Ghannam MZ, Ali AAEM, El Samanoudy MI, Kamel AR. Assessment of The Level of Protein C in Children with Nephrotic Syndrome. Egypt J Hosp Med. 2019;76(3):3828–34.
Alfakeekh K, Azar M, Sowailmi B Al, Alsulaiman S, Makdob S Al, Omair A, et al. Immunosuppressive burden and risk factors of infection in primary childhood nephrotic syndrome. J Infect Public Health [Internet] 2019;12(1):90– 4. Available from: https://doi.org/10.1016/j.jiph.2018.09.006
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
